Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T22:31:34.383Z.
Calculation as of: 2026-10-06T22:31:34.383Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3e31615b66e5acc6c2b7b3f8a521ec69124b31f47383f0f9627e8176a83f275d
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.73B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.70B | N/A | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.78B | N/A | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | N/A | 0.20 | 0.17 | 0.17 |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.83B | N/A | N/A | N/A | N/A |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.84B | N/A | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.60B | N/A | N/A | N/A | N/A |
| Erasca, Inc. (ERAS)vs › | $4.96B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.48B | N/A | 0.39 | 0.39 | 0.39 |
| Waystar Holding Corp. (WAY)vs › | $5.06B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
